XNAS · Healthcare · Medical Devices
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.18 | -0.21 | -16.67% | $19.1M | ❌ Miss | -6.85% | -15.69% | — |
| 2026-03-24 | Q4 2025 | -0.18 | -0.17 | +5.56% | $20.9M | ✅ Beat | -2.09% | -18.56% | -18.30% |
| 2025-11-13 |
| Q3 2025 |
| -0.19 |
| -0.19 |
| +0.00% |
| $20.7M |
| ➖ Inline |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.18 | -0.22 | -22.22% | $20.2M | ❌ Miss | -11.82% | -8.60% | -15.59% |
| 2025-03-20 | Q4 2024 | -0.22 | -0.23 | -4.55% | $17.6M | ❌ Miss | -37.18% | -41.45% | -61.97% |
| 2024-11-07 | Q3 2024 | -0.40 | -0.42 | -5.00% | $19.0M | ❌ Miss | +2.84% | +1.67% | +1.34% |
| 2024-08-12 | Q2 2024 | -0.47 | -0.51 | -8.51% | $16.1M | ❌ Miss | -22.94% | -23.44% | -34.16% |
| 2024-03-21 | Q4 2023 | -0.43 | -0.53 | -23.26% | $17.0M | ❌ Miss | — | — | — |
Showing last 8 quarters.